The startup develops scaffold protein technologies that produce recombinant binder proteins from antibody fragments, offering diagnostic services based on multi-functional recombinant polypeptides. These polypeptides provide enhanced performance in diagnostic applications compared to traditional monoclonal antibodies, facilitating research and treatment development for various diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Developing targeted therapeutics and biologics often requires customizable targeting moieties with high affinity, specificity, and stability. Traditional antibody development can be time-consuming and may not always yield optimal candidates for bispecific or multispecific applications.
Solution
Next Biomed Therapies Oy leverages its patented SH3 scaffold technology to create customizable, recombinant binding proteins for targeted therapeutic applications. Their double-randomized SH3 (drSH3) domains are small (6 kDa), modular, and highly stable, enabling the development of bispecific and multispecific antibodies with enhanced binding affinities. These engineered drSH3 domains can be fused to IgG molecules or other therapeutic proteins, creating novel biopharmaceuticals with improved targeting capabilities and half-life extension. The platform facilitates the rapid generation of targeting modules for a variety of therapeutic platforms, offering a versatile alternative to traditional antibody-based approaches.
Target Audience
The primary customers are pharmaceutical and biotech companies seeking novel targeting technologies for developing biopharmaceuticals, as well as research organizations involved in therapeutic antibody development.
Features
- Patented drSH3 scaffold technology for generating high-affinity targeting domains
- Modular design enabling bispecific and multispecific antibody formats
- Enhanced binding affinity and specificity compared to traditional antibodies
- Improved stability and solubility for robust therapeutic applications
- Customizable loop engineering for targeting any protein of interest
- drSH3-IgG fusion concept for creating next-generation therapeutic antibodies
- Applications include targeted biologics, bispecific antibodies, and plasma half-life extension